You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Dermatology
On demand events
SPD | Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic Dermatitis?
Drs. Amy Paller and Peter Lio led an educational symposium that investigated atopic dermatitis as a risk factor for the development of food allergies. The speakers also discussed the benefits of early intervention in pediatric atopic dermatitis and the potential for disease modification.
Discover how atopic dermatitis can be a risk factor for the development of food allergies
Describe the impact of potential opportunities for early intervention on disease trajectories
Understand the potential for disease modification in atopic dermatitis
Description
Watch Drs. Amy Paller and Peter Lio as they uncover how atopic dermatitis can be a risk factor for the development of food allergies, the benefits of early intervention in pediatric atopic dermatitis, and the potential for disease modification.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.